Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 601 - 650 out of 67,037

Document Document Title
WO/2020/191894A1
Disclosed is a thermally activated delayed fluorescent material, having a structure shown in formula (I), wherein D1 and D2 are different electron donors. In addition, also disclosed is an organic light-emitting diode display device, com...  
WO/2020/192302A1
Disclosed are a pyrimidine-containing tri-substituted imidazole compound having the structure shown in formula (I) and an application thereof. The compound can effectively inhibit EGFR C797S mutations including EGFR ex19del/T790M/C797S a...  
WO/2020/198478A1
The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in ani...  
WO/2020/193341A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2020/194097A1
A quinoxaline derivative that is a novel organic compound is provided. A quinoxaline derivative represented by General Formula (G1) has a structure in which a quinoxaline skeleton is bonded to the 9-position of an anthracene skeleton, th...  
WO/2020/193511A1
The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as HPK1 inhibitors, useful for treating diseases such as cancer.  
WO/2020/192042A1
Provided are an electroluminescent material, a method for preparing the electroluminescent material, and a light-emitting device containing the electroluminescent material. Strong electron withdrawing groups such as a cyano group, pyridi...  
WO/2020/191448A1
The present invention is directed to the tartrate salt of a FAK inhibitor defined by formula (I) below, and the use of that inhibitor for treating a proliferative disease.  
WO/2020/198214A1
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof, which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenera...  
WO/2020/193448A1
The invention provides compounds of formula I wherein: m is 0, 1 or 2; n is 2, 3, 4 or 5; R0 and R1 are both H, or they form a bridge -CH2-C(R4 )=CH-, R4 being CH3 or CH2CH3; R2 and R3 independently are H, F, Cl or (C1-C4)-alkyl; R5 is H...  
WO/2020/193474A1
Described are substituted 2-heteroarylaminobenzenes of general formula (I) and the use thereof as herbicides, in particular for controlling weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influen...  
WO/2020/198567A1
The present disclosure provides novel compounds, compositions comprising the compounds and methods of use thereof.  
WO/2020/188014A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2020/191283A1
Crystalline and amorphous forms of N-(5-((4-ethylpiperazin-1-yl)methyl)pyridin-2-yl-5-fluoro-4- (3-isopropyl-2-methyl-2H-indazol-5-yl)pyrimidin-2-amine (Compound 1) and various salts thereof, preparation methods of these crystalline and ...  
WO/2020/188027A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2020/188299A1
There is herein provided a compound of formula I (I) or a pharmaceutically acceptable salt thereof, wherein the ring comprising Q1 to Q5, R1, m, X1 and ring A have meanings as provided in the description.  
WO/2020/188833A1
[Problem] To provide a manufacturing method for a biaryl amide derivative. [Solution] A manufacturing method for the compound expressed in formula (IM-5) and the compound expressed in formula (I). A manufacturing method for the compoun...  
WO/2020/187292A1
Provided are a class of new compounds which act as a JAK kinase inhibitor, a composition and use thereof. In particular, provided are a class of compounds having a strong JAK kinase inhibitory activity (as represented in formula (1)), or...  
WO/2020/189117A1
A π-conjugated compound according to the present invention has a structure represented by general formula (1), while having a HOMO level of -5.3 eV or more. (In the formula, M represents CX1 or a nitrogen atom; each of X1-X6 represents ...  
WO/2020/188399A1
The present invention relates to a process for the preparation of apalutamide in stable amorphous form. The invention also relates to a novel intermediate crystalline form, called form X, which gives rise to said amorphous form, and a pr...  
WO/2020/191052A1
The present disclosure provides a method for treating symptomatic orthostatic hypotension using a potent selective antagonist of N-methyl-D-aspartate receptor subunit 2B (NMDA-GluN2B or NR2B).  
WO/2020/191261A1
The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.  
WO/2020/187674A1
The present invention relates to crystalline cobimetinib hemisuccinate and a process for its preparation. The invention also relates to a pharmaceutical composition comprising crystalline cobimetinib hemisuccinate, preferably in a predet...  
WO/2020/188049A1
The present invention relates to compounds of the general formula (I): (I), wherein V, W, M, R, R and Y have the designations cited below, or a pharmaceutically or veterinary acceptable salt, hydrate or solvate thereof, and to processes ...  
WO/2020/006031A8
Provided are compounds of Formula (I): including compounds of Formulas (II), (III) and (IV), wherein X, R1, R2, R3 and n are as defined herein, and pharmaceutically acceptable salts thereof, and methods for their use and production. Thes...  
WO/2020/190762A1
The invention provides a macromolecule-supported compound of formula (I) or (II). Macromolecule-supported compounds of the invention, comprising macromolecular support linked to one or more TLR agonists, are recognized by TLRs (e.g., TLR...  
WO/2020/188223A1
The present invention relates to functionalized supports and the use thereof for the diagnosis of diseases. It discloses a method for characterizing microvesicles present in a sample of biological fluid from a subject, comprising a step ...  
WO/2020/182929A1
The present invention relates to compounds of formula (I): Formula (I) wherein the variables are defined as in claim 1, to compositions comprising at least one of said compounds and at least one agriculturally suitable auxiliary, to the ...  
WO/2020/184379A1
Provided are: a trisubstituted benzene compound represented by general formulae (1) and (2); and an organic electroluminescence (EL) element having a pair of electrodes and at least a pair of organic layers interposed therebetween, the o...  
WO/2020/184670A1
The present invention relates to a method for monodeuterated lower alkylating an amine moiety of a compound which contains an amine that is protected by an aralkyl group, wherein a monodeuterated lower alkyl is introduced into the amine ...  
WO/2020/182587A1
The present invention relates to mixtures of sterically hindered amines of the formulae (1 ) and (2) wherein at least one of the radicals Z1, Z2, Z3, Z4, Z5 and Z6 is C1-C18 alkyloxy or C5-C7 cycloalkyloxy and the remaining of the radica...  
WO/2020/182649A1
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.  
WO/2020/185983A1
Provided herein are free base crystalline forms, crystalline salts, and solvates of Compound B.  
WO/2020/182666A1
The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to, to said compounds for use in therapy, to pharmaceutical compositio...  
WO/2020/182648A1
The invention provides novel imidazole pyrazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein X1, RA and R3 to R7 are as described herein: (I) Further provided are pharmaceutical compo...  
WO/2020/182018A1
The present invention relates to a nitrogen heterocyclic compound, a preparation method therefor and use thereof, and specifically relates to a compound as shown in formula I, a stereoisomer or a tautomer of the compound or a mixture the...  
WO/2020/181386A1
The present application relates to novel fluorinated derivatives, to processes for their preparation, to compositions comprising them, and to their use in therapy. More specifically, it relates to compounds useful in the treatment of dis...  
WO/2020/184578A1
Provided is a novel elF2α phosphorylation promoter that is a compound represented by general formula (1) or a pharmaceutically acceptable salt of said compound. In the formula, R1 is a substituted or unsubstituted aryl group, a substitu...  
WO/2020/182109A1
A crystal form of a deuterium atom-substituted indole formamide derivative with structure shown in formula I and a preparation method therefor. The crystal form of the compound represented by formula (I) exhibits good stability and may b...  
WO/2020/182100A1
The present disclosure provides a compound and methods of preparing the compound. The compound has anti-microbial and anti-mite properties and can be bonded to materials such as fiber and synthetic polymer. The compound may also be used ...  
WO/2020/185982A1
Provided herein are free base crystalline forms, crystalline salts, solvates, amorphous free base, and cocrystals of Compound A.  
WO/2020/181555A1
Crystal form A of N,N'-(10,17-dihydro-3,6,21,24-tetraoxa-9,11,16,18-tetrazohex ahexane-1,26-di-yl)bis(4-(6,8-dichloro-2-methyl-1,2,3,-tetra hydroisoquinoline-4-yl). The crystal form has good light stability, high-temperature stability, a...  
WO/2020/181395A1
The present application relates to a rinse-off composition comprising an oil phase and an aqueous surfactant matrix, wherein one or more active agents are dissolved in one or more non-polar, water-immiscible solvents, and the oil phase i...  
WO/2020/181247A1
The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.  
WO/2020/036949A8
Provided are compounds of Formula (I): Formula (I), including compounds of Formulas (II), (III), (IV), (V) and (VI), wherein X, R1, R2, R3, R4 and n are as defined herein,and pharmaceutically acceptable salts thereof, and methods for the...  
WO/2020/177653A1
The present invention relates to a pyrazine derivative, an application thereof in inhibiting SHP2, and a compound of formula (I) or pharmaceutically acceptable salts, esters, isomers, solvates, prodrugs or isotope labels thereof. The str...  
WO/2020/180285A1
A water monitoring device monitors and maintains swimming pool chemistry. The device mixes reagents with water in flowcells. The water chemistry is detected by measuring the light transmitted through the flowcells. The water monitoring d...  
WO/2020/160193A3
The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.  
WO/2020/181040A1
Cyclic amino-pyrazinecarboxamide compounds, salts, and pharmaceutical compositions for use in the treatment of disease, such as cancer, are disclosed herein. The disclosed compounds are useful, among other things, in the treating of dise...  
WO/2020/180959A1
The present application provides pyrazolyl pyrimidinylamine inhibitors of cyclin-dependent kinase 2 (CDK2), as well as pharmaceutical compositions thereof, and methods of treating cancer using the same.  

Matches 601 - 650 out of 67,037